Lv41
542 积分 2023-09-06 加入
Tumour targetable and microenvironment-responsive nanoparticles simultaneously disrupt the PD-1/PD-L1 pathway and MAPK/ERK/JNK pathway for efficient treatment of colorectal cancer
2小时前
已完结
Searching in the immune checkpoint black box
2个月前
已完结
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
2个月前
已完结
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
3个月前
已完结
Emerging evidence for adapting radiotherapy to immunotherapy
3个月前
已完结
A new strategy for immunotherapy of microsatellite‐stable (MSS)‐type advanced colorectal cancer: Multi‐pathway combination therapy with PD‐1/PD‐L1 inhibitors
3个月前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
4个月前
已完结
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
4个月前
已完结
Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing
7个月前
已完结
LW-213 induces immunogenic tumor cell death via ER stress mediated by lysosomal TRPML1
7个月前
已完结
皖公网安备34019202002308
